177 results about "Diagnostic tools" patented technology

The invention discloses a method for constructing a machine learning model based on cerebellar subregion multi-modal radiomics. According to the method, [18F] FDG PET metabolic features and 3DT1 W MRI structural features of a cerebellar subregion are extracted, a random forest classification model is constructed after feature selection, and high-precision identification of the Alzheimer's disease (AD) and a cognitive normal (CN) is realized in combination with SHAP analysis. According to the method, the multi-modal radiomics characteristics of the cerebellar subregion are integrated for the first time, the accuracy and interpretability of AD early diagnosis are improved, and a non-invasive and efficient diagnosis tool is provided for clinic.

The invention relates to the technical field of attention deficit hyperactivity disorder detection, and discloses a device for detecting cognitive and developmental conditions of children with hyperactivity disorder, which comprises a handle, a head-mounted device, a bracelet, a hierarchical adaptive algorithm module, a multi-dimensional execution module and a data fusion and analysis module, a multi-mode sensing module is arranged in each of the handle, the head-mounted device and the bracelet; a motion capture unit, a high-sensitivity key array, a tactile feedback module and a wireless transmission module are integrated in the handle, and a wireless electroencephalogram acquisition module, a miniature near infrared spectrum module and an eye movement tracking module are integrated in the head-mounted device. According to the invention, through deep fusion of a multi-dimensional cognitive evaluation system and gamepad hardware, the device not only breaks through the limitation of the traditional neuropsychological test in methodology, but also realizes refined capture of ADHD heterogeneity characteristics in the technical level, and provides a hardware basis for establishing an objective and quantitative diagnostic tool with high ecological efficiency.

The application provides a CPU platform fault log recording method and device, comprising: receiving the running log data stream output by the CPU debugging serial port in real time; collecting the sampling value of the key power supply voltage and monitoring the hardware signal line to obtain the restart event signal and the shutdown event signal; packaging into a structured log recording unit; and writing the compressed log data block back to the flash memory; in response to the external reading instruction, reading the log data block from the specified log area of the flash memory and transmitting to the host end diagnostic tool; reorganizing and displaying in time sequence for fault analysis. The application can construct a log recording channel completely independent of the main CPU and operating system without increasing any additional hardware cost, ensuring that even in the most extreme system failure scenario, the complete context information at the fault moment can be reliably saved, thereby greatly improving the diagnosis efficiency and accuracy of the occasional fault.

The invention discloses a highly inert Gd-DOTA-based contrast agent with a hydrophobic side chain as well as a preparation method and application of the highly inert Gd-DOTA-based contrast agent, and two novel Gd-DOTA-based contrast agents Gd-L1 and Gd-L2 are successfully developed by respectively connecting hydrophobic 3-phenyl propylamine and 3, 3-diphenyl propylamine to Gd-DOTABA. The two novel Gd-DOTA-based contrast agents remarkably improve the chemical inertness of the complex, the dissociation half-life period of the complex in a 1 M HCl solution at 37 DEG C is about 5 times that of Gd-DOTA, and a powerful guarantee is provided for clinical safety; the MRI (Magnetic Resonance Imaging) performance of the liver in a mouse shows that Gd-L1 is equivalent to commercially available Gd-BOPTA and is suitable for imaging of a liver and gall system; after the Gd-L2 is combined with the human serum albumin, the longitudinal relaxation rate is obviously increased (r1 = 14.8 mM <-1 > s <-1 >, 1.4 T, 37 DEG C), the blood elimination half-life period in a rabbit model is about 18 minutes, and the Gd-L2 is suitable for vascular MRI (Magnetic Resonance Imaging). The two contrast agents avoid the spleen residual problem, the organ accumulation possibility is reduced, and a safer and more efficient MRI diagnostic tool is provided for clinic.

Disclosed herein is a method for diagnosing a medical condition in a patient. The method comprises: obtaining, from the patient, a plurality of physiological values; implementing a first model configured to determine risk values for at least one of a plurality of medical conditions, based on the physiological values. Implementing the first model comprises: obtaining a first risk value for the at least one medical condition, based on a first one of the obtained physiological values; and weighting the first risk value based on a second one of the obtained physiological values, to determine a total risk value of the at least one medical condition for the patient.

The invention relates to the technical field of nano antibodies, in particular to an anti-FcRH5 nano antibody and application thereof. The invention provides an anti-FcRH5 nano antibody with high affinity and specificity, and the anti-FcRH5 nano antibody is based on a single-domain heavy chain variable region structure from camelidae and has the advantages of small molecular weight, high stability, strong tissue penetrability, easiness in engineering modification and the like. The nano antibody specifically recognizes and is combined with a high-expression and stable-expression target spot on the surface of a multiple myeloma cell through a complementary determining region of the nano antibody. The nano antibody disclosed by the invention can be used as a core recognition element for constructing various treatment or diagnosis tools such as chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates or immunodetection probes and the like. According to the technical scheme, the technical problem that an anti-FcRH5 antibody with high quality and definite functionality is lacked in the prior art can be solved. The nano antibody provided by the invention has remarkable clinical transformation and industrialization advantages, and promotes multiple myeloma treatment to multi-target collaborative iteration.

This invention discloses a combination of biomarkers for the auxiliary diagnosis of chronic pain comorbid with depression and its application, belonging to the fields of in vitro diagnostics (IVD) and clinical testing technology. The biomarker combination includes interleukin-6 (IL-6), interleukin-12 (IL-12), and the concentration ratio of kynurenic acid to 3-hydroxykynurenine (KYNA / 3-HK). This invention also discloses the application of this biomarker combination in an in vitro diagnostic kit for chronic pain comorbid with depression. Experimental results show that the diagnostic efficacy of this biomarker combination (AUC=0.871) is significantly better than that of a single biomarker, effectively distinguishing patients with chronic pain comorbid with depression from those without chronic pain, providing an objective auxiliary diagnostic tool for clinical practice.

This invention relates to the field of depression monitoring and intervention technology, and discloses a depression monitoring and intervention system based on an internet hospital and heart rate variability (HRV). The system includes: a multimodal physiological signal acquisition module for simultaneously acquiring raw HRV signals, skin conductance fluctuations, and respiratory rate data; a signal processing module for preprocessing and feature extraction of the raw signals to obtain multidimensional feature vectors; and a depression level inference module that constructs a multilayer perceptron neural network, taking as input the multidimensional feature vector containing multidimensional HRV features, skin conductance fluctuations, and respiratory rate statistics, and outputting probability values ​​for no depression, mild depression, and moderate to severe depression levels. This invention establishes an intelligent management mechanism for internet hospitals for the first time, collecting multidimensional physiological data of patients with depression in real time through wearable monitoring units. Based on the dynamic trends of physiological data characteristics, it can serve as an auxiliary diagnostic tool for psychiatry, especially suitable for early screening and remote follow-up of depression, reducing the consumption of medical resources.

- Method and device for determining and using a diagnostic tool comprising a temperature aging spectrum. - The method (P) comprises a step (E1) for receiving at least one temperature curve relating to a given geographical location, a processing step (E2) comprising a series of successive substeps (E2A, E2B, E2C, E2D, E2E), implemented iteratively for different values ​​of a characteristic time associated with a type of material, comprising a substep (E2A) for filtering the temperature curve using a first-order filter having said characteristic time as its time constant, a substep (E2B) for applying an aging law, a substep (E2C) for performing an accumulation over a given sliding period, a substep (E2D) for extracting a value corresponding to an aging criterion, and a substep (E2E) for associating this extracted value with the characteristic time.The pairs of values ​​obtained at the end of the iterations allow the formation of a temperature aging spectrum, and a step (E3) to perform comparisons, at least from this spectrum, to carry out a diagnosis. Figure for the abstract: Fig. 4.

The invention relates to an application of a nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases, the nano antibody is an NB21 nano antibody, and the NB21 nano antibody has an amino acid sequence as shown in SEQ ID No.12. The invention also relates to an application of the nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases. The antibody can specifically block a Wnt / beta-catenin pathway, effectively inhibit expression of proinflammatory factors and relieve inflammatory response of heart tissues, so that occurrence and development of cardiovascular diseases are intervened. The nano antibody has significant advantages in the aspects of intervention accuracy, conversion reliability and the like, and preclinical results show that the nano antibody can improve occurrence and development of ischemic cardiomyopathy; the pharmaceutical composition can be used for treating heart failure, myocarditis and adriamycin cardiomyopathy, can be expanded to systemic inflammatory diseases, realizes the trans-boundary application of one drug with multiple targets, fully verifies the anti-inflammatory effectiveness and safety through in-vivo and in-vitro experimental data, provides new targets, diagnostic tools and accurate intervention schemes for diagnosis and treatment of cardiovascular diseases and systemic inflammatory diseases, and has wide application prospects. The obvious scientific innovation significance and clinical transformation value are realized.

1. Name of the designed product: vehicle diagnostic instrument (PT100). 2. Use of the designed product: for vehicle detection. 3. Design points of the designed product: in shape. 4. Picture or photo best indicating the design points: perspective view 1.

A method for improving waste gas collection efficiency of an arc-shaped top suction gas-collecting hood based on an interface mass-energy ratio comprises the following steps: constructing a physical geometric model of the 1: 1 arc-shaped top suction gas-collecting hood by adopting space claim based on an ANSYS 2024 R1 simulation platform; defining the ratio of turbulent kinetic energy to mass flux on the mass-energy ratio interface as an interface mass-energy ratio; sequentially setting a plurality of groups of comparison working conditions by taking the number of the outlet air pipes, the layout of the outlet air pipes and the size of the outlet air pipes as single variables to finish simulation; exporting result data, and drawing a scatter diagram of the collection efficiency, the vortex volume and the interface mass-energy ratio; and the number, layout and size of the outlet air pipes are optimized according to the result, and the collection efficiency is maximized. According to the method, the limitation of relying on subjective judgment in the traditional empirical design is overcome, so that the performance of the flow field has comparability, and a clear scientific basis and a diagnostic tool are provided for subsequent optimization.

A diagnostic tool includes a sensor for capturing at least one biosignal produced by a patient's heart and a computer device that implements a neural network iteratively trained via machine learning to generate a prediction about a heart condition of the patient. After the neural network is trained, the computer device can convert the at least one biosignal to a multi-dimensional input matrix for the deep neural network generated from a number (N) of biosignals captured by the sensor. The computer device then processes the multi-dimensional input matrix through the deep neural network, which subsequently outputs the prediction about the heart condition of the patient.

In one embodiment, there is provided a device for performing a plurality of respiratory diagnostic tests, comprising: a housing, a sensor assembly, and control circuitry configured to receive signals from the sensor assembly; wherein the device has a first configuration in which the device is configured to perform a first respiratory diagnostic test and a second configuration in which the device is configured to perform a second respiratory diagnostic test, wherein in the first configuration an airflow channel is defined through the device housing, the sensor assembly being configured to measure at least a first property of air in the airflow channel during the first respiratory diagnostic test, and wherein in the second configuration the airflow channel is modified relative to the first configuration, the sensor assembly being used to measure at least a second property of air in the airflow channel during the second respiratory diagnostic test. In another embodiment there is provided a stand-alone device is designed for performing an impulse oscillometry test.

The invention discloses a cat parvovirus VP2 protein nano antibody as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The amino acid sequence of the cat parvovirus VP2 protein nano antibody is as shown in SEQ ID NO. 1 or SEQ ID NO. 2. According to the invention, an alpaca is immunized by using FPV VP2 protein, a phage display nano antibody library is constructed, and two nano antibodies 3D6 and 1B9 with strong specificity and high affinity are obtained through multiple rounds of panning and identification. Through identification, the nano antibodies 3D6 and 1B9 can be specifically combined with FPV and VP2 proteins, and have high affinity and remarkable virus neutralizing activity. The nano antibody can be used for preparing a detection reagent or kit for feline parvovirus infection, and rapid and accurate diagnosis is realized; the compound can also be used as an active component to prepare a therapeutic drug, and provides a special therapeutic scheme for FPV infection. The nano antibody provides an important material basis for developing a novel diagnostic tool and a specific therapeutic drug aiming at the feline parvovirus.

Disclosed herein is a blood-based two-part diagnostic tool designed to diagnose a pre-symptomatic neurodegenerative disease. The first part consists of assays designed for amplifying and sequencing predetermined regions of cell-free DNA. The second part consists of python-derived conduits that analyze methylation characteristics to identify neuronal-derived DNA and provide a diagnosis of a pre-symptomatic neurodegenerative disease.

Use of one or more markers to identify and sort cells that have been engineered to comprise a synthetic chromosome encoding the marker(s), with said cells expressing said marker(s) encoded on the synthetic chromosome. The marker is typically but not limited to a cluster of differentiation (CD), wherein the CD has been truncated or otherwise modified so that the biological function of the CD is lost or remarkably reduced. The modified CD is typically used to sort cells to obtain a desired population of cells containing the synthetic chromosome, or i) to ensure that a cell population administered to a subject, e.g., suffering from cancer, reaches the target tissue, ii) to ensure that a cell population administered to a subject, e.g., suffering from cancer, stays at the desired site within the body of the subject during a treatment regimen, iii) to make it possible to turn on a kill switch comprised in the synthetic chromosomes of the cells of the cell population if the cell population is present at undesired sites in the body, or iv) to use as a diagnostic tool.

This provides a molecular diagnostic tool useful for the efficient and accurate characterization of the discriminative and functional properties of iPSC-derived dopaminergic neurons. [Solution] A computer-based method for identifying determined dopaminergic progenitor cells within an in vitro population of neural progenitor cells is provided, comprising: receiving a test dataset containing data such as gene expression profile information relating to an in vitro population of neural progenitor cells; querying a gene expression reference database and comparing the test dataset with the gene expression reference database, wherein the gene expression reference database contains gene expression profile information of the desired determined dopaminergic progenitor cells; and outputting a computer-calculated label classification that includes an indication of whether or not the in vitro population of neural progenitor cells contains the determined dopaminergic progenitor cells.

Methods, systems, and devices for host system diagnostic testing are described. A diagnostic tool including a diagnostic executable stored to an external memory may evaluate a system including a host subsystem and a memory subsystem. Upon initialization, the diagnostic executable may configure trace points in one or more layers (e.g., associated with an operating system) of the host subsystem based on dependencies (e.g., libraries) stored to the external memory, and may receive, from the host subsystem, first data collected at the trace points, directly from a host system buffer, or from the memory subsystem. Concurrent to the collection procedure, the diagnostic executable may perform processing operations on the first data to generate second data, which may be associated with one or more metrics of system performance. The second data is stored to the external memory, and may be utilized to evaluate the system.

The present invention is in the field of pre-functionalized nanoparticles (NPs). It more particularly relates to the use of NPs pre-functionalized with self-assembled monolayers (SAMs), and also to the use of NPs functionalized with biomolecules, such that the NPs are stable in solution. These NPs can be used in a variety of applications, in particular as diagnostic tools, depletion tools of target molecules in solution, and therapeutic tools.

The invention belongs to the technical field of medical diagnosis, and particularly relates to a visual column diagram construction method for identifying and diagnosing suppurative and tuberculous lumbar major muscle abscesses and interactive application. According to the invention, it is found that six indexes including serum uric acid (UA), thrombin time (TT), neutrophil absolute value (NEUT #), age (Age), fever (Fever) and erythrocyte sedimentation rate (ESR) are related to the type of the lumbar major muscle abscess, and a visual column diagram construction method for identifying and diagnosing suppurative and tuberculous lumbar major muscle abscess and interactive application are invented. And a first visual and quantifiable column diagram (Nomogram) prediction model for differential diagnosis of lumbar major muscle abscess is provided for the field. The technical problem that an abstract mathematical prediction model is converted into a visual graphic diagnosis tool which is intuitive in form and convenient to operate is solved, so that the visual graphic diagnosis tool can be separated from dependence on specific computing equipment, and clinical medical staff can quickly and accurately apply the visual graphic diagnosis tool on a diagnosis and treatment site conveniently.

According to the application of the urine TRPV5 as the biomarker in chronic kidney disease diagnosis and risk assessment, it is found for the first time that the TRPV5 and the detectable fragment thereof exist in the urine, the content of the TRPV5 and the detectable fragment thereof in the urine is in positive correlation with the chronic kidney disease CKD, the CKD can be diagnosed by detecting the content of the TRPV5 in the urine, and the application of the TRPV5 and the detectable fragment thereof in the diagnosis and risk assessment of the chronic kidney disease in the diagnosis and risk assessment of the chronic kidney disease is achieved. The invention also provides a specific in-vitro diagnosis method and a kit. According to the in-vitro diagnosis method, multiple defects of the existing CKD diagnosis technology are overcome, a brand-new diagnosis tool which is noninvasive, sensitive and specific and can be used for staging and prognosis evaluation is provided, and the in-vitro diagnosis method has remarkable scientific and technological advancement and wide clinical application prospects.

The invention provides a prostate cancer multi-target joint detection kit, a detection system and application, multiple targets in the kit are selected from an MSMB gene, an AMACR gene, a PCGEM1 gene, an MALAT1 gene and an MIR4435 gene, and the kit further comprises a primer and probe combination aiming at each marker. According to the method, the diagnosis accuracy can be improved, the weight interpretation model can be constructed, the clinical decision can be optimized, and a non-invasive and high-compliance auxiliary diagnosis tool is provided for the problems of traumatic detection and gray areas in the prior art.

The invention relates to a kit for early differential diagnosis of EBV-HLH and a method for auxiliary diagnosis of EBV-HLH. The kit comprises an EBV nucleic acid detection reagent and a miRNA-375 detection reagent. The kit provided by the invention is used for combined detection of EBV-DNA and miRNA-375 in a detection sample, and when an EBV-DNA detection result is greater than 5000 copies / mL and a miRNA-375 detection CT value is less than 35, suspected EBV-HLH is diagnosed. The invention not only provides a specific diagnostic index for EB infected diseases, but also serves as a reliable auxiliary diagnostic tool for EBV-HLH and other EB virus infection related diseases. When the kit provided by the invention is used for identifying and diagnosing EBV-HLH, the sensitivity and the accuracy are higher.

This specification discloses a blood-based, two-part diagnostic tool designed to diagnose neurodegenerative diseases before symptom onset. The first component consists of an assay designed to amplify and sequence a pre-identified region of cell-free DNA. The second component consists of a Python-derived pipeline that analyzes methylation signatures to identify neuron-derived DNA and provide a diagnosis of neurodegenerative diseases before symptom onset.

1. Name of the product in this design: Automotive Diagnostic Tool. 2. Purpose of this design: For diagnosing and detecting automotive malfunctions. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1.

Disclosed herein are methods for diagnostic tools to calculate the risk of acute rejection in a renal allograft recipient.

The invention provides an intelligent monitoring method, system and device for a vehicle storage battery and a medium, and belongs to the technical field of vehicle storage batteries. The method comprises the steps that storage battery type parameters are written into a non-volatile memory of a vehicle control unit through a vehicle diagnostic tool; the vehicle control unit reads the parameters and sends an initialization message to the intelligent battery sensor through an LIN bus for parameter calibration; periodically requesting the state information of the storage battery and judging the feedback credibility of the sensor; when the feedback is credible, non-standard electricity utilization, low electric quantity and low health degree are directly judged based on the sensor data, and an alarm is given; and when the feedback is not credible, T-BOX time information is received, recently credible SOC, SOH, temperature and time difference are used as BP neural network input, and judgment and alarm are executed after the current battery state is estimated. And the continuity of the key monitoring function is ensured.